Immunologic and Molecular Mechanisms in Inflammatory Bowel Disease

Surgical Clinics of North America

Volumn 87, Issue 3, 2007, Pages 681-696

  Ince, M Nedim ^a   Elliott, David E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 23; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; B LYMPHOCYTE; CLINICAL FEATURE; COLITIS; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; ENTERITIS; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; HEREDITY; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 34250026738     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.03.005     Document Type: Review

References (98)

1. Clevers H. At the crossroads of inflammation and cancer. Cell 118 (2004) 671-674
2. Bamias G., Nyce M.R., De La Rue S.A., et al. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 143 (2005) 895-904
3. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
4. Hommes D.W., Sterringa G., van Deventer S.J., et al. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 10 (2004) 245-250
5. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
6. Rutgeerts P., Goboes K., Peeters M., et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338 (1991) 771-774
7. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
8. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000) 7010-7017
9. Cario E., Rosenberg I.M., Brandwein S.L., et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 164 (2000) 966-972
10. Hermiston M.L., and Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270 (1995) 1203-1207
11. Cobrin G.M., and Abreu M.T. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206 (2005) 277-295
12. Salzman N.H., Ghosh D., Huttner K.M., et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422 (2003) 522-526
13. Cash H.L., Whitham C.V., Behrendt C.L., et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313 (2006) 1126-1130
14. Wehkamp J., Salzman N.H., Porter E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005) 18129-18134
15. Rescigno M., Urbano M., Valzasina B., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2 (2001) 361-367
16. Rimoldi M., Chieppa M., Salucci V., et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 6 (2005) 507-514
17. Smith P.D., Ochsenbauer-Jambor C., and Smythies L.E. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 206 (2005) 149-159
18. Joossens S., Reinisch W., Vermeire S., et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122 (2002) 1242-1247
19. Mizoguchi A., and Bhan A.K. A case for regulatory B cells. J Immunol 176 (2006) 705-710
20. Korzenik J.R., and Podolsky D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5 (2006) 197-209
21. Metwali A., Setiawan T., Blum A.M., et al. Induction of CD8+ regulatory T cells in the intestine by Heligmosomoides polygyrus infection. Am J Physiol Gastrointest Liver Physiol 291 (2006) G253-G259
22. Szabo S.J., Kim S.T., Costa G.L., et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 (2000) 655-669
23. Zheng W., and Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89 (1997) 587-596
24. Ivanov I.I., McKenzie B.S., Zhou L., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006) 1121-1133
25. Williams L.M., and Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8 (2007) 277-284
26. Izcue A., Coombes J.L., and Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212 (2006) 256-271
27. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
28. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
29. Nielsen O.H., Kirman I., Rudiger N., et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 38 (2003) 180-185
30. Fujino S., Andoh A., Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
31. Iweala O.I., and Nagler C.R. Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol Rev 213 (2006) 82-100
32. Marks D.J., Harbord M.W., MacAllister R., et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367 (2006) 668-678
33. Monteleone G., Mann J., Monteleone I., et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem 279 (2004) 3925-3932
34. Monteleone G., Kumberova A., Croft N.M., et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108 (2001) 601-609
35. Te Velde A.A., Verstege M.I., and Hommes D.W. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis 12 (2006) 995-999
36. Neurath M.F., Fuss I., Pasparakis M., et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27 (1997) 1743-1750
37. Neurath M.F., Fuss I., Kelsall B.L., et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
38. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
39. Zhang Z., Zheng M., Bindas J., et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12 (2006) 382-388
40. Mangan P.R., Harrington L.E., O'Quinn D.B., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
41. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
42. Becker C., Dornhoff H., Neufert C., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177 (2006) 2760-2764
43. Boirivant M., Fuss I.J., Chu A., et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188 (1998) 1929-1939
44. Berg D.J., Zhang J., Weinstock J.V., et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123 (2002) 1527-1542
45. Fuss I.J., Boirivant M., Lacy B., et al. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 168 (2002) 900-908
46. Boirivant M., Pallone F., Di G.C., et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131 (2006) 1786-1798
47. Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
48. Shull M.M., Ormsby I., Kier A.B., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
49. Davidson N.J., Leach M.W., Fort M.M., et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 184 (1996) 241-251
50. Li M.O., Wan Y.Y., Sanjabi S., et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24 (2006) 99-146
51. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7 (2001) 1118-1122
52. Li M.O., Sanjabi S., and Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25 (2006) 455-471
53. Powrie F., Carlino J., Leach M.W., et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 183 (1996) 2669-2674
54. Asseman C., Mauze S., Leach M.W., et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1004
55. Rudensky A.Y., and Campbell D.J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 203 (2006) 489-492
56. Podolsky D.K., Lobb R., King N., et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 92 (1993) 372-380
57. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
58. Tysk C., Lindberg E., Jarnerot G., et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29 (1988) 990-996
59. Halfvarson J., Bodin L., Tysk C., et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124 (2003) 1767-1773
60. Kufer T.A., Banks D.J., and Philpott D.J. Innate immune sensing of microbes by Nod proteins. Ann N Y Acad Sci 1072 (2006) 19-27
61. Gaya D.R., Russell R.K., Nimmo E.R., et al. New genes in inflammatory bowel disease: lessons for complex diseases?. Lancet 367 (2006) 1271-1284
62. Lala S., Ogura Y., Osborne C., et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 125 (2003) 47-57
63. Ogura Y., Lala S., Xin W., et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 52 (2003) 1591-1597
64. Kobayashi K.S., Chamaillard M., Ogura Y., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
65. Girardin S.E., Boneca I.G., Viala J., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 (2003) 8869-8872
66. Maeda S., Hsu L.C., Liu H., et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307 (2005) 734-738
67. Radlmayr M., Torok H.P., Martin K., et al. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 122 (2002) 2091-2092
68. Abreu M.T., Taylor K.D., Lin Y.C., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123 (2002) 679-688
69. Ahmad T., Marshall S.E., and Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol 12 (2006) 3628-3635
70. Rutgeerts P., Van A.G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
71. Peltekova V.D., Wintle R.F., Rubin L.A., et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36 (2004) 471-475
72. Panwala C.M., Jones J.C., and Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161 (1998) 5733-5744
73. Annese V., Valvano M.R., Palmieri O., et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 12 (2006) 3636-3644
74. Hue S., Ahern P., Buonocore S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 203 (2006) 2473-2483
75. Kullberg M.C., Jankovic D., Feng C.G., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 203 (2006) 2485-2494
76. Uhlig H.H., McKenzie B.S., Hue S., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25 (2006) 309-318
77. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
78. Ishii K., Kurita-Taniguchi M., Aoki M., et al. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy. Immunol Lett 98 (2005) 280-290
79. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
80. Franchimont D., Vermeire S., El H.H., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
81. Torok H.P., Glas J., Tonenchi L., et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 112 (2004) 85-91
82. Torok H.P., Glas J., Tonenchi L., et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127 (2004) 365-366
83. Fukata M., Michelsen K.S., Eri R., et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288 (2005) G1055-G1065
84. Fukata M., Chen A., Klepper A., et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131 (2006) 862-877
85. Ince M.N., Elliott D.E., Setiawan T., et al. Heligmosomoides polygyrus induces TLR4 on murine mucosal T cells that produce TGFbeta after lipopolysaccharide stimulation. J Immunol 176 (2006) 726-729
86. Bohm S.K., and Kruis W. Probiotics: do they help to control intestinal inflammation?. Ann N Y Acad Sci 1072 (2006) 339-350
87. Lee J., Mo J.H., Shen C., et al. Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homoeostasis. Curr Opin Gastroenterol 23 (2007) 27-31
88. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
89. Pierik M., Joossens S., Van S.K., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 12 (2006) 1-8
90. Sutmuller R.P., den Brok M.H., Kramer M., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116 (2006) 485-494
91. Lodes M.J., Cong Y., Elson C.O., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113 (2004) 1296-1306
92. Gewirtz A.T., Vijay-Kumar M., Brant S.R., et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1157-G1163
93. Lengeling R.W., Mitros F.A., Brennan J.A., et al. Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents. Clin Gastroenterol Hepatol 1 (2003) 160-169
94. Maizels R.M., and Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 3 (2003) 733-744
95. Elliott D.E., Summers R.W., and Weinstock J.V. Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol 21 (2005) 51-58
96. Summers R.W., Elliott D.E., Urban Jr. J.F., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005) 825-832
97. Summers R.W., Elliott D.E., Urban Jr. J.F., et al. Trichuris suis therapy in Crohn's disease. Gut 54 (2005) 87-90
98. Elliott D.E., Setiawan T., Metwali A., et al. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. Eur J Immunol 34 (2004) 2690-2698